July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
PK/PD modeling to identify optimal binding affinity of an intravitreally administered anti-IL33 antibody to maintain target engagement in vitreous and retina for the treatment of AMD
Author Affiliations & Notes
  • isabel FIGUEROA
    Genentech, BELMONT, California, United States
  • Gerald Nakamura
    Genentech, BELMONT, California, United States
  • Laetitia Comps-Agrar
    Genentech, BELMONT, California, United States
  • Joyce Chan
    Genentech, BELMONT, California, United States
  • Elaine Mai
    Genentech, BELMONT, California, United States
  • Racquel Corpuz
    Genentech, BELMONT, California, United States
  • Jack Bevers
    Genentech, BELMONT, California, United States
  • Kelly Loyet
    Genentech, BELMONT, California, United States
  • Menno Van Lookeren Campagne
    Genentech, BELMONT, California, United States
  • Amrita kamath
    Genentech, BELMONT, California, United States
  • Footnotes
    Commercial Relationships   isabel FIGUEROA, None; Gerald Nakamura, None; Laetitia Comps-Agrar, None; Joyce Chan, None; Elaine Mai, None; Racquel Corpuz, None; Jack Bevers, None; Kelly Loyet, None; Menno Van Lookeren Campagne, None; Amrita kamath, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 246. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      isabel FIGUEROA, Gerald Nakamura, Laetitia Comps-Agrar, Joyce Chan, Elaine Mai, Racquel Corpuz, Jack Bevers, Kelly Loyet, Menno Van Lookeren Campagne, Amrita kamath; PK/PD modeling to identify optimal binding affinity of an intravitreally administered anti-IL33 antibody to maintain target engagement in vitreous and retina for the treatment of AMD. Invest. Ophthalmol. Vis. Sci. 2018;59(9):246.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Blocking of IL33 binding to ST2 receptor (rST2) has been proposed as a therapeutic strategy to mitigate IL33 pathogenic activity in AMD. To test this hypothesis, intra-vitreal (ITV) administration of an anti-IL33 antibody (mAb) to neutralize IL33 in vitreous and retina was evaluated. In the ocular tissues, IL33 binds to the membrane bound form of ST2 (rST2) resulting in IL33 pro-inflammatory action. However, it also binds to the decoy soluble ST2 receptor (sST2). We use a mathematical model to determine the optimal binding affinity (Kd) required for an anti-IL33 mAb to maintain >90% levels of target neutralization in vitreous and retina.

Methods : A compartmental PK/PD model incorporating the ITV PK of the mAb as well as the binding of IL33 to both rST2 and sST2 was developed to simulate the administration of an anti-IL33 mAb and evaluate its ability to block IL33-ST2 interactions in vitreous and retina. To inform this model, Kd of IL33 to sST2 and rST2 were measured by surface plasmon resonance at 37°C. Levels of sST2 and IL33 in human vitreous were measured by an ELISA assay in post-mortem vitreous of control and AMD donors.

Results : Vitreal sST2 (concentration 20-70pM in control subjects and 10-200pM in AMD patients) was identified as a potential sink for IL-33 (IL-33 concentration in vitreous < 10pM). However, the model suggested that these concentrations result in a minimal fraction (<10%) of IL33 bound to sST2 based on the measured Kd of IL33 for sST2 (4 - 8 nM). Measured Kd of IL33 to rST2 was 62 pM. Considering typical PK properties for a mAb after ITV injection (mono-exponential decay with a vitreal volume of distribution of 4 mL and a vitreal half-life of 6 to 9 days), Kd values equal to 0.1nM to 1nM are predicted to maintain >90% target neutralization in vitreous for 9 to 13 weeks after a dose of 10 mg/eye. Assuming a retina to vitreous partition coefficient equal to 1:10, the corresponding duration of target coverage in retina is estimated to be between 4 to 9 weeks.

Conclusions : PK/PD model simulations identified optimal Kd of an anti-IL33 mAbs to be in the range of 0.1 to 1 nM to maintain greater than 90% neutralization of IL33 in vitreous and retina, if dosed at 10 mg/eye every 4 to 9 weeks. In addition, based on the model, sST2 does not appear to be a major sink for IL33 in the vitreous.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×